GLP-1 Drugs May Trigger a Rare, Painful Nerve Condition from Rapid Blood Sugar Drops | Research

The takeaway

Six patients developed diabetic lumbosacral radiculoplexus neuropathy (DLRPN) — a rare, debilitating nerve condition — after starting GLP-1 drugs, likely triggered by rapid blood sugar reduction and weight loss.

35-52 lbs weight loss
Rapid weight loss and HbA1c drops preceded DLRPN onset in all 6 patients

What the researchers found

Six patients developed DLRPN after GLP-1 RA use, with all showing substantial weight loss (35-52 lbs) and rapid HbA1c decline, suggesting rapid glycemic correction as the trigger mechanism.

Why it matters

As millions start GLP-1 drugs, clinicians need to recognize that rapid blood sugar improvements — usually celebrated — can paradoxically cause serious nerve damage in some patients.

How the study worked

Retrospective case series of 6 patients with DLRPN onset following GLP-1 receptor agonist exposure.

What this study cannot tell us

Very small case series (n=6); no control group; cannot prove causation vs. coincidence; DLRPN can occur with any rapid glycemic improvement.

How to read the evidence

Case series (n=6) — lowest level of clinical evidence but important for safety signal identification with a rare condition.

When this study was published

Published in 2026, representing an emerging safety concern as GLP-1 drug use expands dramatically.

The bigger picture

This highlights an important but underrecognized risk of potent glucose-lowering therapies: the paradox that dramatically improving diabetes control too quickly can itself cause serious complications.

Questions still open

Should GLP-1 drugs be started at lower doses with slower titration in patients with very high baseline HbA1c?
What is the true incidence of DLRPN among GLP-1 drug users versus the general diabetic population?

Common questions

What is DLRPN and why is it linked to GLP-1 drugs?

DLRPN is a rare nerve condition causing sudden severe leg pain and weakness. It's triggered by rapid blood sugar improvements — and GLP-1 drugs can lower blood sugar and HbA1c very quickly, potentially precipitating this condition.

Should I be worried about this if I take a GLP-1 drug?

DLRPN is very rare. The risk appears highest in people with very high starting HbA1c who experience rapid improvement. If you develop sudden leg pain or weakness, contact your doctor promptly.

Read the original research

Diabetic lumbosacral radiculoplexus neuropathy after glucagon-like peptide 1 receptor agonist use: A case series.

Journal of the neurological sciences, 481, 125755

View on PubMed ↗Publisher’s paper ↗

Citation

Chandrashekhar, Swathy; Davalos, Long; Pradhan, Richeek; Paul, Pritikanta. (2026). Diabetic lumbosacral radiculoplexus neuropathy after glucagon-like peptide 1 receptor agonist use: A case series.. Journal of the neurological sciences, 481, 125755. https://doi.org/10.1016/j.jns.2026.125755